Congress passed a Farm Bill in 2018 that included historic provisions to legalize hemp, the low THC cultivars of the Cannabis sativa L. species. This landmark legislation changes how hemp and hemp-derived products like cannabidiol (CBD) are regulated in the U.S. To help the herbal products industry understand the new regulatory landscape, AHPA has expanded this Status Report and to answer industry questions about the new legal landscape.

Wednesday March 6, 2018 at the Fullerton Arboretum. Bus departs Anaheim Convention Center at 1:00 PM and returns at 5:00 PM .

Attend this webinar to learn how to successfully traverse the NDI notification process and avoid common pitfalls that can result in FDA objections.

Recorded September 20, 2018 -- Duration: 2 hours

Recorded May 22, 2018 -- Member cost: $150. Nonmember cost: $350.

This two-part webinar provides an update on the elements of current Good Manufacturing Practice (cGMP) regulations (21 CFR 111) that have been the primary focus of recent FDA inspections. Experts also provide strategies to respond to an FDA  483 in order to avoid a warning letter.